Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus PEDIAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus PEDIAMYCIN.
E.E.S. 200 vs PEDIAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may be bacteriostatic or bactericidal depending on concentration and organism.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
250-500 mg orally every 6 hours; maximum 2 g/day.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
The terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function. In patients with severe hepatic impairment, half-life may be prolonged to 5-6 hours. The short half-life necessitates frequent dosing (every 6-8 hours) to maintain therapeutic levels.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
PEDIAMYCIN (erythromycin ethylsuccinate) is primarily excreted via the biliary route (60-70% as unchanged drug and metabolites) with significant fecal elimination. Renal excretion accounts for only 5-15% of the dose, mostly as inactive metabolites. Less than 5% is excreted unchanged in urine.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic